Skip to main content
. 2011 Apr 22;8:184. doi: 10.1186/1743-422X-8-184

Table 2.

Sequence alignment of amino acid residues of the S1 glycoprotein of IBV strains with the M41 strain

Strains Deletions1 Insertions2 Cleavage recognition motifs
CQ8 119(2)GL, 140(2)NS RRTGRa
CQ9 21(1)D, 118(1)G 72(7)YTNGNDV HRRRRb
MS1 21(1)D, 118(1)G 72(7)YTNGNDV HRRRRb
PT1 21(1)D, 118(1)G 72(7)YTNGNDV RRSRRc
PT2 117(2)GV, 286(1)N RRLRRd
PT3 21(1)D, 118(1)G 72(7)YTNGNDV RRSRRc
PT4 21(1)D, 118(1)G 72(7)YTNGNDV RRSRRc
BT 119(2)GS RRFRRe
Y4 117(2)GI, 286(1)N RRFRRe
Y9 117(2)GI, 286(1)N RRFRRe
FML 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HY 117(2)GV, 286(1)N RRLRRd
HY41 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HY42 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HY51 23(1)S, 118(1)G 72(7)YTNGNDV, 286(1)G RRFRRe
HY52 23(1)S, 118(1)G 72(7)YSNGNDV RRSKRf
HY1 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HY2 23(1)S, 118(1)G 72(7)YSNGNDV RRSKRf
HY3 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
KY 24(1)N, 119(2)GS HRRRRb
LZ1 24(1)N, 119(2)GS HRRRRb
LZ2 24(1)N, 119(2)GS HRRRRb
LZ3 24(1)N, 119(2)GS HRRRRb
LH 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
SL 24(1)N, 119(2)GS HRRRRb
ST1 119(2)GS RRFRRe
ST3 119(2)GS RRFRRe
WL 21(1)D, 118(1)G 72(7)YTNGNDV HRRRRb
XD2 119(2)GS RRFRRe
XD3 24(1)N, 119(2)GS RRFRRe
XN 24(1)N, 119(2)GS RRFRRe
XN1 25(1)N, 119(2)GS HRRRRb
XN2 119(2)GS RRFRRe
GL1 21(1)D, 118(1)G 72(7)YTNGNDV HRRRRb
GL2 117(2)GI, 289(1)N RRLRRd
GL 25(1)N, 119(2)GS HRRRRb
HEZ 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
LC 118(1)G 72(7)YTNGNDV, 286(1)S RRFRRe
LC1 117(2)GI RRFRRe
LC2 117(2)GI RRFRRe
LC3 117(2)GI RRFRRe
LC4 117(2)GI RRFRRe
LC5 117(2)GI RRFRRe
LC6 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
LC7 117(2)GI RRFRRe
LC8 117(2)GI RRFRRe
LC9 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
NN 117(2)GI, 286(1)N RRLRRd
YL08 117(2)GI, 286(1)N RRLRRd
YL4 24(1)S, 118(1)G 72(7)YTNGNDV RRFRRe
YL6 24(1)N, 119(2)GS HRRRRb
HN08 119(2)GS RRFRRe
HN1 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HN2 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HN31 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HN32 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HN33 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HN34 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HN41 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HN42 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HN43 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HN44 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
WH1 24(1)N, 119(2)GS HRRRRb
WH2 24(1)N, 119(2)GS HRRRRb
WH3 25(1)N, 119(2)GS HRRRRb
WH4 25(1)N, 119(2)GS HRRRRb
LYG 25(1)N, 119(2)GS HRRRRb
NJ RRFRRe
HZ1 25(1)N, 119(2)GS HRRRRb
HZ2 25(1)N, 119(2)GS HRRRRb
HZ3 25(1)N, 119(2)GS HRRRRb
HZ4 21(1)D, 118(1)G 72(7)YTNGNDV RRFRRe
HZ5 25(1)N, 119(2)GS HRRRRb
HZ6 25(1)N, 119(2)GS HRRRRb
HZ7 25(1)N, 119(2)GS HRRRRb
HZ8 25(1)N, 119(2)GS HRRRRb
HZ9 25(1)N, 119(2)GS HRRRRb
QZ1 24(1)N, 119(2)GS HRRRRb
QZ2 24(1)N, 119(2)GS HRRRRb
QZ3 24(1)N, 119(2)GS HRRRRb

1 positions of residues in deduced amino acid sequences of the S1 protein of the M41 vaccine strain;

2 positions of residues in deduced amino acid sequences of the S1 protein of the M41 strain between which the residue(s) of other IBVs was (were) inserted.

a, RRTGR: Arg-Arg-Thr-Gly-Arg (1/80); b, HRRRR: His-Arg-Arg-Arg-Arg (28/80); c, RRSRR: Arg-Arg-Ser-Arg-Arg (3/80); d, RRLRR: Arg-Arg-Leu-Arg-Arg 5/80; e, RRFRR: Arg-Arg-Phe-Arg-Arg (41/80); f, RRSKR Arg-Arg-Ser-Lys-Arg (2/80).